Skip to main content
Fig. 5 | BMC Urology

Fig. 5

From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Fig. 5

Genomic mutations together with RUNX3 pathway signature to predict IO/TKI benefit. (A) Waterfall plot showing genomic mutations ranked by RUNX3 signature expression. P values, Chi-square test. *, P < 0.05. (B) PFS benefit of IO/TKI versus TKI monotherapy defined by SETD2 mutational status and RUNX3 signature. HR and P values, Cox regression model; wt, wild type. (C-F) PFS of IO/TKI or TKI monotherapy in subgroups of (C) high-RUNX3 signature/SETD2-wt, (D) low-RUNX3 signature/SETD2-wild type, (E) high-RUNX3 signature/SETD2-mutant, (F) low-RUNX3 signature/SETD2-mutant. P values, Kaplan-Meier analysis, and log-rank test

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us